Introduction
autoimmune neuromuscular disease
MUSCLE WEAKNESS, AUTOIMMUNE DISEASES, SECONDARY
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease that causes fatigable muscle weakness. Extraocular and eyelid muscles are particularly susceptible to weakness, though other muscles for chewing, talking, and swallowing are also frequently involved.The neonatal Fc receptor (FcRn) is critical to the regulation of IgG levels in the serum. FcRn regulates IgG degradation, thereby prolonging its circulating half‐life. Targeting the FcRn pathway dramatically reduces circulating IgG, thus supporting its evaluation for the treatment of autoantibody‐mediated autoimmune diseases.The primary objectives of this study were to assess the safety and tolerability profile of low‐volume SC injections of batoclimab and to determine its effects on total IgG, IgG subclasses (1–4), and anti‐AChR‐IgG antibody levels in patients with MG. The secondary objectives were to assess the pharmacokinetics (PK) of SC batoclimab and to examine its effects on MG‐specific outcome measures to gather insights into the design of a possible efficacy trial in the future.